Sprycel

What Sprycel is used for

Sprycel is indicated for the treatment of paediatric patients with: newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase (Ph+ CML CP) or Ph+ CML CP resistant or intolerant to prior therapy including imatinib. newly diagnosed Ph+ acute lymphoblastic leukaemia (ALL) in combination with chemotherapy. Sprycel is indicated for the treatment of adult patients with: newly diagnosed Philadelphia-chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase; chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate; Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy. Sprycel is indicated for the treatment of paediatric patients with: newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.

Approved use, as published by the European Medicines Agency.

Key facts

Brand

Sprycel

Active substance

dasatinib (anhydrous)

Disease area

Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Medicine group

Antineoplastic agents

ATC code

L01EA02

Marketing authorisation holder

Bristol-Myers Squibb Pharma EEIG

Authorised in the EU since

2006

Official information

• Sprycel: European public assessment report (EPAR), product information and package leaflet, on the EMA website

In the USA

Same active substance: Phyrago, Sprycel

In India

• Dasatinib: 42 brands in India